{"id":60776,"date":"2024-02-28T07:07:41","date_gmt":"2024-02-28T07:07:41","guid":{"rendered":"https:\/\/medsname.com\/tenvir-af\/"},"modified":"2026-05-21T05:27:39","modified_gmt":"2026-05-21T05:27:39","slug":"tenvir-af","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/tenvir-af\/","title":{"rendered":"Tenvir AF"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:16px 20px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin-top:0;\">Quick Answer &mdash; Tenvir AF (Tenofovir Alafenamide 25 mg)<\/h3>\n<ul>\n<li><strong>Substan\u021b\u0103 activ\u0103:<\/strong> tenofovir alafenamide fumarate (TAF) 25 mg, oral tablet, taken once daily with food.<\/li>\n<li><strong>Indica\u021bie principal\u0103 \u00een aceast\u0103 list\u0103:<\/strong> chronic hepatitis B virus (HBV) infection in adults &mdash; long-term suppression with substantially less kidney and bone exposure than older TDF.<\/li>\n<li><strong>Mecanism:<\/strong> nucleotide reverse-transcriptase inhibitor (NRTI). Same active metabolite as tenofovir disoproxil, but a different prodrug that releases tenofovir inside hepatocytes and lymphocytes.<\/li>\n<li><strong>Versus TDF:<\/strong> ~90% lower plasma tenofovir, ~6&ndash;7&times; higher intracellular drug. Same antiviral potency. Lower risk of renal toxicity and bone mineral density loss.<\/li>\n<li><strong>Eficacitate HBV:<\/strong> non-inferior to TDF for HBV DNA suppression at 96 weeks; significantly better renal and bone safety markers in head-to-head trials.<\/li>\n<li><strong>Avertizare reactivare HBV:<\/strong> severe acute exacerbation can occur on discontinuation. Never stop without specialist supervision.<\/li>\n<\/ul>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Ce beneficii ofer\u0103 MedsBase:<\/strong> Produc\u0103tor certificat WHO-GMP \u00b7 Ambalaj discret \u00b7 Livrare la nivel mondial \u00b7 Peste 1.400 de recenzii verificate <a href=\"https:\/\/medsbase.com\/ro\/reviews\/\">ale clien\u021bilor<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Fiecare comand\u0103 este acoperit\u0103 de politica noastr\u0103 de <a href=\"https:\/\/medsbase.com\/ro\/medsbase-re-shipment-assurance-policy\/\"><strong>Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 dac\u0103 coletul dumneavoastr\u0103 nu sose\u0219te \u00een 20 de zile lucr\u0103toare, \u00eel relivr\u0103m.<\/p>\n<h3>De ce s\u0103 comanzi de la MedsBase<\/h3>\n<p>Medicamentele noastre generice sunt procurate de la produc\u0103tori certifica\u021bi WHO-GMP \u0219i expediate la nivel mondial \u00een ambalaje discrete \u0219i simple \u2014 f\u0103r\u0103 denumirea medicamentului pe exteriorul coletului. Pl\u0103\u021bile cu cardul sunt procesate printr-un procesor reglementat (descrierile de pe extrasul de cont includ un procesor de pl\u0103\u021bi cu card reglementat \u2014 niciodat\u0103 \u201cMedsBase\u201d sau numele vreunui medicament). Accept\u0103m \u0219i criptomonede \u0219i transferuri bancare SEPA. Fiecare comand\u0103 este sus\u021binut\u0103 de Politica noastr\u0103 de Asigurare pentru Relivrare.<\/p>\n<h2 class=\"wp-block-heading\">What Is Tenvir AF?<\/h2>\n<p>Tenvir AF is an oral tablet containing <strong>tenofovir alafenamide fumarate 25 mg<\/strong> (TAF), manufactured by Cipla. Each pack typically contains 30 film-coated tablets.<\/p>\n<p>TAF is the second-generation prodrug of tenofovir, designed to fix the renal and bone toxicity issues seen with the older TDF (tenofovir disoproxil) prodrug. The originator brand is <strong>Vemlidy<\/strong> (Gilead, FDA-cleared for chronic hepatitis B in 2016). Same active drug as TDF, dramatically different pharmacokinetics.<\/p>\n<h2 class=\"wp-block-heading\">What Is Tenvir AF Used For?<\/h2>\n<ul>\n<li><strong>Chronic hepatitis B (CHB) in adults<\/strong> &mdash; first-line oral antiviral, especially in patients with chronic kidney disease (CKD), osteoporosis, age &gt; 60, or pre-existing TDF-related renal\/bone toxicity.<\/li>\n<li><strong>infec\u021bia cu HIV-1<\/strong> &mdash; component of combination regimens (most commonly co-formulated with FTC, dolutegravir or bictegravir, or rilpivirine). Not used as monotherapy in HIV.<\/li>\n<li><strong>Profilaxia pre-expunere la HIV (PrEP)<\/strong> &mdash; the TAF + emtricitabine combination (Descovy) is approved for PrEP in cisgender men and transgender women; TDF\/FTC remains preferred for at-risk people who could become pregnant.<\/li>\n<\/ul>\n<p>TAF is <strong>prime\u0219te,<\/strong> used to treat hepatitis C, herpes viruses, or any non-retroviral \/ non-HBV infection.<\/p>\n<h2 class=\"wp-block-heading\">Why TAF Instead of TDF?<\/h2>\n<p>TDF is rapidly hydrolysed in plasma to tenofovir, exposing the kidneys to high circulating drug levels for hours. TAF stays intact in plasma far longer because it is a more stable prodrug, and is preferentially activated by lymphocyte and hepatocyte intracellular esterases (cathepsin A, CES1). The net result:<\/p>\n<table style=\"border-collapse:collapse;width:100%;font-size:14px;\">\n<thead>\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:8px;border:1px solid #ddd;text-align:left;\">Marker<\/th>\n<th style=\"padding:8px;border:1px solid #ddd;text-align:left;\">TDF 300 mg<\/th>\n<th style=\"padding:8px;border:1px solid #ddd;text-align:left;\">TAF 25 mg<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:8px;border:1px solid #ddd;\">Plasma tenofovir AUC<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">High (reference)<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">~90% mai sc\u0103zut<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:8px;border:1px solid #ddd;\">Intracellular TFV-DP in PBMCs<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Reference<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">~6&ndash;7&times; higher<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #ddd;\">eGFR decline at 96 wks (HBV)<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Modest, dose-related<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Significantly less<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:8px;border:1px solid #ddd;\">Hip + spine BMD change<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Small reduction<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Less reduction; sometimes recovery on switch<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #ddd;\">Lipid effect<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Mildly favourable (lipid-lowering)<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Mildly unfavourable (raises LDL\/HDL)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The lipid effect is the one trade-off. In patients with established cardiovascular disease, TDF may be preferred. For most HBV patients with renal or bone risk factors, TAF is the cleaner long-term option.<\/p>\n<h2 class=\"wp-block-heading\">Dosage and How to Take Tenvir AF<\/h2>\n<ul>\n<li><strong>Chronic hepatitis B:<\/strong> one 25 mg tablet once daily with food.<\/li>\n<li><strong>HIV (combination regimens):<\/strong> 25 mg if combined with non-boosted agents; 10 mg if combined with a CYP3A inhibitor (cobicistat, ritonavir).<\/li>\n<\/ul>\n<p>Take with food &mdash; bioavailability rises by approximately 65% with a moderate-fat meal. Swallow whole. Missed doses: take as soon as remembered if within 18 hours; otherwise skip and resume the next scheduled tablet.<\/p>\n<p><strong>Renal-impairment dose adjustment:<\/strong> no adjustment required for CrCl &ge; 15 mL\/min. Below 15 mL\/min, only use in patients on chronic haemodialysis (TAF dosed after dialysis on dialysis days). TAF is not recommended in non-dialysis end-stage renal disease.<\/p>\n<p><strong>Afectare hepatic\u0103:<\/strong> no adjustment for mild or moderate; not recommended in decompensated cirrhosis (Child-Pugh C).<\/p>\n<h2 class=\"wp-block-heading\">Efecte Secundare<\/h2>\n<p><strong>Frecvente:<\/strong> headache (~10%), abdominal pain (~5%), fatigue, cough, nausea, back pain. Usually mild and self-limiting.<\/p>\n<p><strong>Mai pu\u021bin frecvente, dar importante:<\/strong><\/p>\n<ul>\n<li><strong>Lipid changes<\/strong> &mdash; expect modest rise in LDL-C, HDL-C, total cholesterol, and triglycerides. Recheck lipids at 3 and 12 months. Consider statin therapy if cardiovascular risk is elevated.<\/li>\n<li><strong>Cre\u0219terea \u00een greutate<\/strong> &mdash; HIV trials show several kg over 1&ndash;2 years on TAF-containing regimens vs TDF (regression of TDF&#8217;s mild lipid-lowering effect appears to drive part of this). Less established in HBV monotherapy.<\/li>\n<li><strong>Lactic acidosis with severe hepatomegaly<\/strong> &mdash; rare NRTI class effect; stop on unexplained progressive abdominal pain, rapid breathing, severe fatigue.<\/li>\n<li><strong>Severe acute hepatitis B exacerbation on stopping<\/strong> &mdash; same flare risk as TDF. Requires monitoring for at least 6 months after discontinuation.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Interac\u021biuni medicamentoase<\/h2>\n<ul>\n<li><strong>Strong P-gp inducers<\/strong> &mdash; rifampicin, rifabutin, carbamazepine, phenytoin, oxcarbazepine, St John&#8217;s wort &mdash; lower TAF exposure. Avoid co-administration.<\/li>\n<li><strong>CYP3A inhibitors<\/strong> &mdash; cobicistat, ritonavir &mdash; significantly raise TAF exposure. Use the 10 mg form if co-administered with a boosted PI\/INSTI regimen.<\/li>\n<li><strong>Alte medicamente nefrototoxice<\/strong> &mdash; less of a concern than with TDF, but caution still advised with cidofovir, IV aminoglycosides, IV amphotericin B, high-dose NSAIDs.<\/li>\n<li><strong>Other tenofovir-containing products<\/strong> &mdash; do not combine TAF with TDF, adefovir, or another TAF-containing product.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Who Should Not Take Tenvir AF?<\/h2>\n<ul>\n<li>Known hypersensitivity to tenofovir alafenamide or any excipient<\/li>\n<li>Severe renal impairment (CrCl &lt; 15 mL\/min) not on chronic haemodialysis<\/li>\n<li>Decompensated cirrhosis (Child-Pugh C)<\/li>\n<li>Concurrent strong P-gp inducer where switching is not feasible<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Depozitare<\/h2>\n<p>Store below 30&deg;C in the original bottle with desiccant. Protect from moisture. Keep out of reach of children.<\/p>\n<h2 id=\"faqs\">\u00centreb\u0103ri frecvente<\/h2>\n<h3 class=\"wp-block-heading\">Is Tenvir AF the same as Vemlidy?<\/h3>\n<p>Yes &mdash; same molecule (tenofovir alafenamide 25 mg), same indication (chronic hepatitis B), same once-daily dosing. Tenvir AF is Cipla&#8217;s licensed generic version. Vemlidy is the originator (Gilead).<\/p>\n<h3 class=\"wp-block-heading\">If TAF is better, why does anyone still take TDF?<\/h3>\n<p>Several reasons: TDF has a 20-year safety database; TDF lowers LDL cholesterol slightly (TAF does the opposite); pregnancy data is more mature for TDF; and TDF is materially cheaper. For young patients without renal or bone issues, TDF remains a perfectly reasonable first-line choice. TAF is preferred when renal or bone safety matters most.<\/p>\n<h3 class=\"wp-block-heading\">Can I switch from Tenvir (TDF) to Tenvir AF?<\/h3>\n<p>Yes, and many patients do, especially after years on TDF when small declines in eGFR or BMD become relevant. The switch is straightforward: stop TDF, start TAF the next day. Antiviral suppression is maintained because both deliver the same active metabolite. Renal markers usually improve within 3&ndash;6 months. Recheck eGFR, urine protein, phosphate at 3 months post-switch.<\/p>\n<h3 class=\"wp-block-heading\">Will Tenvir AF cure my hepatitis B?<\/h3>\n<p>No oral antiviral cures HBV. Tenofovir alafenamide suppresses replication so completely that viral DNA usually becomes undetectable and liver inflammation resolves &mdash; but the cccDNA template inside hepatocytes is not eliminated. Around 1&ndash;3% of patients per year achieve functional cure (HBsAg loss). For most patients, treatment is long-term.<\/p>\n<h3 class=\"wp-block-heading\">Should I expect weight gain on Tenvir AF?<\/h3>\n<p>HIV combination data show modest weight gain on TAF regimens vs TDF, of around 2&ndash;4 kg over 96 weeks. The effect is smaller in HBV monotherapy and is partly explained by reversal of TDF&#8217;s slight metabolic disadvantage. If weight gain is concerning, baseline lipid and glucose monitoring is reasonable.<\/p>\n<h3 class=\"wp-block-heading\">Can I take Tenvir AF in pregnancy?<\/h3>\n<p>Pregnancy data for TAF is growing but is still less mature than for TDF. For HBV in late pregnancy (week 28+) to prevent vertical transmission, TDF is the preferred choice based on the larger safety database. If you are stable on TAF and become pregnant, discuss with your hepatologist before switching &mdash; the call depends on viral load, fibrosis stage, and trimester.<\/p>\n<h3 class=\"wp-block-heading\">Is Tenvir AF active against HIV resistance mutations?<\/h3>\n<p>TAF and TDF have an identical resistance profile because they deliver the same active metabolite. Both retain activity against most thymidine-analogue mutations (TAMs) but are reduced in efficacy against the K65R reverse-transcriptase mutation. Resistance testing should guide regimen choice when available.<\/p>\n<h3 class=\"wp-block-heading\">Do I need any blood tests before starting Tenvir AF?<\/h3>\n<p>Yes &mdash; baseline HBV DNA, HBeAg \/ anti-HBe, HBsAg, ALT\/AST, full blood count, eGFR, urinalysis (proteinuria), serum phosphate, lipid panel, and HIV antibody\/antigen test. Treatment monitoring then settles to every 3&ndash;6 months for stable patients.<\/p>\n<h3 class=\"wp-block-heading\">Does Tenvir AF interact with statins, blood-pressure drugs, or contraception?<\/h3>\n<p>No clinically significant interaction with statins, ACE inhibitors, ARBs, beta-blockers, calcium-channel blockers, or hormonal contraception. The few real interactions are with strong P-gp inducers (rifampicin, anticonvulsants) and CYP3A boosters (cobicistat, ritonavir).<\/p>\n<h3 class=\"wp-block-heading\">Where can I order Tenvir AF?<\/h3>\n<p>You can order Tenvir AF directly from MedsBase. We supply genuine Cipla stock with worldwide shipping. Treatment of chronic hepatitis B should be supervised by a hepatologist or gastroenterologist with HBV DNA, ALT, eGFR, and HBsAg\/anti-HBs monitoring at appropriate intervals.<\/p>\n<h2 class=\"wp-block-heading\">Declinare de responsabilitate<\/h2>\n<p>The information on this page is for educational purposes and is not a substitute for professional medical advice. Treatment of chronic hepatitis B and HIV requires baseline workup, ongoing specialist monitoring, and individualised regimen choice. Do not start, stop, or switch tenofovir-based therapy without consulting a qualified clinician.<\/p>\n<p class=\"medsbase-bundle-link-2026-05-01\" data-marker=\"mb-bundle-link-prep-starter-pack\">Tenvir-AF (TAF\/FTC) handles HIV PrEP but does not cover bacterial STIs; if you&#8217;d like layered protection many users pair it with doxy-PEP \u2014 our <a href='\/ro\/prep-starter-pack\/'>Pachetul de pornire PrEP (Tenvir-EM + doxiciclin\u0103 100 mg)<\/a> bundles the established TDF\/FTC PrEP regimen with doxycycline for syphilis, chlamydia, and gonorrhoea prevention.<\/p>\n<p class=\"medsbase-link-boost-2026-05-08\" data-marker=\"mb-link-boost-tenvir-em\">Pacien\u021bii care iau <a href=\"https:\/\/medsbase.com\/ro\/tenvir-af\/\">Tenvir AF<\/a> for hepatitis B who also require HIV pre-exposure prophylaxis should note that <a href=\"https:\/\/medsbase.com\/ro\/tenvir-em\/\">Tenvir EM (tenofovir disoproxil fumarat 300 mg + emtricitabin\u0103 200 mg)<\/a> is the approved dual-component PrEP regimen combining TDF with emtricitabine for comprehensive HIV prevention.<\/p>\n<p class=\"medsbase-link-boost-2026-05-10\" data-marker=\"mb-link-boost-avonza\">Clinics building ART formularies around <a href=\"https:\/\/medsbase.com\/ro\/tenvir-af\/\">Tenvir AF (tenofovir alafenamide 25 mg)<\/a> as a renal-sparing backbone also stock <a href=\"https:\/\/medsbase.com\/ro\/avonza\/\">Avonza (TDF \/ lamivudine \/ efavirenz)<\/a> for cost-conscious patients in whom the older TDF formulation&#8217;s renal profile is clinically acceptable.<\/p>\n<p class=\"medsbase-link-boost-2026-05-21\" data-marker=\"mb-link-boost-tavin-em\">Patients tolerating <a href=\"https:\/\/medsbase.com\/ro\/tenvir-af\/\">Tenvir AF (tenofovir alafenamide 25 mg)<\/a> but seeking a lower-cost daily PrEP option without the TAF\/FTC premium may consider <a href=\"https:\/\/medsbase.com\/ro\/tavin-em\/\">Tavin EM (tenofovir disoproxil 300 mg + emtricitabin\u0103 200 mg)<\/a>, the older TDF\/FTC PrEP backbone with the largest evidence base.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Alternative conexe<\/h3>\n<p>Alte produse din <strong>Afec\u021biuni cronice<\/strong> pe care clien\u021bii le vizualizeaz\u0103 de asemenea:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/ebasil\/\">Ebasil<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/budecort-inhaler\/\">Budecort Inhalator<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/fluvoxin\/\">Fluvoxin<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/arkamin-h\/\">Arkamin-H<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/ivepred\/\">Ivepred<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Trateaz\u0103 infec\u021bia cu HIV<br \/>\n\u2705 Reduce \u00eenc\u0103rc\u0103tura viral\u0103<br \/>\n\u2705 Protects kidneys<br \/>\n\u2705 Decreases bone loss<br \/>\n\u2705 \u00cembun\u0103t\u0103\u021be\u0219te calitatea vie\u021bii<\/p>\n<p><strong>Tenvir AF<\/strong> con\u021bine <strong>Tenofovir<\/strong> <strong>Alafenamide<\/strong>.<\/p>","protected":false},"featured_media":60777,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3334,3304],"product_tag":[3335,4920,4921],"class_list":{"0":"post-60776","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-hepatitis-medication","9":"product_cat-hiv-medication","10":"product_tag-tenofovir","11":"product_tag-tenofovir-alafenamide","12":"product_tag-tenvir-af","14":"first","15":"instock","16":"shipping-taxable","17":"purchasable","18":"product-type-variable","19":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product\/60776","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/comments?post=60776"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media\/60777"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media?parent=60776"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_brand?post=60776"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat?post=60776"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_tag?post=60776"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}